This review summarizes the clinical features, etiology, and treatment of neuroleptic malignant syndrome, a potentially lethal complication of neuroleptic exposure.
Offers clinicians a synthesis on NMS recognition and care; leaves open need for prospective trials on prevention.
The neuroleptic malignant syndrome (NMS) occurs as a hypersensitivity response in certain patients exposed to neuroleptics. It is a relatively rare, but potentially lethal complication, the incidence of which may have been underestimated. Recent interest in NMS has arisen due to the recognition that specific therapy may now be available. This review summarises the clinical features and discusses recent ideas regarding aetiology and treatment.
No takes yet. Share an insight, caveat, or question.
Abbott et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: